Literature DB >> 32329911

Functional Characterization of PHEX Gene Variants in Children With X-Linked Hypophosphatemic Rickets Shows No Evidence of Genotype-Phenotype Correlation.

Bixia Zheng1, Chunli Wang1, Qiuxia Chen2, Ruochen Che2, Yugen Sha2, Fei Zhao2, Guixia Ding2, Wei Zhou1, Zhanjun Jia1, Songming Huang2,3, Ying Chen2, Aihua Zhang2,3.   

Abstract

X-linked hypophosphatemia (XLHR) is caused by loss-of-function mutations in the phosphate regulating endopeptidase homolog X-linked (PHEX) gene. Considerable controversy exists regarding genotype-phenotype correlations in XLHR. The present study describes the clinical features and molecular genetic bases of 53 pediatric patients with XLHR. Overall, 47 different mutations were identified, of which 27 were not previously described in the literature or entered in the Human Gene Mutation Database (HGMD). A high prevalence (72.34%) of truncating variants was observed in XLHR patients. The clinical presentation and severity of XLHR did not show an evident correlation between the truncating and non-truncating mutation types in our cohort. To further delineate the characteristics of PHEX variants underlying this nonsignificant trend, we assessed the effects of 10 PHEX variants on protein expression, cellular trafficking, and endopeptidase activity. Our results showed that the nonsense mutations p.Arg567*, p.Gln714*, and p.Arg747* caused a reduction of protein molecular weight and a trafficking defect. Among seven non-truncating mutations, the p.Cys77Tyr, p.Cys85Ser, p.Ile281Lys, p.Ile333del, p.Ala514Pro, and p.Gly572Ser mutants were not secreted into the medium and remained trapped inside cells in an immature form, whereas the p.Gly553Glu mutant was terminally glycosylated and secreted into the medium. We further assessed the endopeptidase activity of the p.Gly553Glu mutant using a quenched fluorogenic peptide substrate and revealed that the activity of p.Gly553Glu significantly reduced to 13% compared with the wild type, which indicated disruption of catalytic function. These data not only support the clinical results showing no correlation between disease severity and the type of PHEX mutation but also provide helpful molecular insights into the pathogenesis of XLHR.
© 2020 American Society for Bone and Mineral Research. © 2020 American Society for Bone and Mineral Research.

Entities:  

Keywords:  GENOTYPE-PHENOTYPE CORRELATION; PHEX; XLHR

Mesh:

Substances:

Year:  2020        PMID: 32329911     DOI: 10.1002/jbmr.4035

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  8 in total

Review 1.  Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium.

Authors:  Michaël R Laurent; Jean De Schepper; Dominique Trouet; Nathalie Godefroid; Emese Boros; Claudine Heinrichs; Bert Bravenboer; Brigitte Velkeniers; Johan Lammens; Pol Harvengt; Etienne Cavalier; Jean-François Kaux; Jacques Lombet; Kathleen De Waele; Charlotte Verroken; Koenraad van Hoeck; Geert R Mortier; Elena Levtchenko; Johan Vande Walle
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-19       Impact factor: 5.555

2.  Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy.

Authors:  Avivit Brener; Yael Lebenthal; Roxana Cleper; Livia Kapusta; Leonid Zeitlin
Journal:  Ther Adv Endocrinol Metab       Date:  2021-03-16       Impact factor: 3.565

3.  Novel PHEX gene locus-specific database: Comprehensive characterization of vast number of variants associated with X-linked hypophosphatemia (XLH).

Authors:  Soodabeh Sarafrazi; Sean C Daugherty; Nicole Miller; Patrick Boada; Thomas O Carpenter; Lauren Chunn; Kariena Dill; Michael J Econs; Scott Eisenbeis; Erik A Imel; Britt Johnson; Mark J Kiel; Stan Krolczyk; Prameela Ramesan; Rebecca Truty; Yves Sabbagh
Journal:  Hum Mutat       Date:  2021-12-05       Impact factor: 4.700

Review 4.  Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review.

Authors:  Claudia Maria Jurca; Oana Iuhas; Kinga Kozma; Codruta Diana Petchesi; Dana Carmen Zaha; Marius Bembea; Sanziana Jurca; Corina Paul; Alexandru Daniel Jurca
Journal:  Genes (Basel)       Date:  2022-08-04       Impact factor: 4.141

5.  Clinical and genetic characteristics of 29 Chinese patients with X-linked hypophosphatemia.

Authors:  Tian Xu; Xiaohui Tao; Zhenlin Zhang; Hua Yue
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-19       Impact factor: 6.055

6.  Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy.

Authors:  Rafi Brener; Leonid Zeitlin; Yael Lebenthal; Avivit Brener
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-15       Impact factor: 6.055

7.  Clinical and Genetic Characteristics of 153 Chinese Patients With X-Linked Hypophosphatemia.

Authors:  Xiaoyun Lin; Shanshan Li; Zhenlin Zhang; Hua Yue
Journal:  Front Cell Dev Biol       Date:  2021-06-01

8.  Long-term dental intervention and laboratory examination in a patient with Vitamin D-dependent rickets type I: A case report.

Authors:  An-Qi Liu; Li-Shu Zhang; Hao Guo; Mei-Ling Wu; Tian-Yi Li; Kun Xuan; Ke-Wen Wei
Journal:  Medicine (Baltimore)       Date:  2020-10-09       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.